Q32 Bio
Immunotherapy drugs targeting innate and adaptive immune regulators
- Sector
- Biotech
- Federal grants
- None on recordNo awards found in SBIR/STTR, NIH, NSF or DoD records.
- Private capital raised
- None on recordNo Form D filings on SEC EDGAR. Some raises are not filed.
- Federal contracts
- None on recordNo federal contract awards found.
- Granted patents
- 3
- 11 pending · first 2021
- Rank in peer group#339 of 1449
Capital timeline
No federal awards or Form D filings are on record for this company.
Many early companies raise without filing a Form D, or have not yet won a federal award. New records appear here as the sources update.
Checked: SEC EDGAR Form D through Oct 23, 2026; SBIR and STTR awards through Oct 21, 2026; USAspending contract awards
Founder? Add funding contextStanding among 1449 peers
Line = medianBiotech · Molecule
- Granted patents#339 · top 23%
Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.
Founders and team
No founders are linked to this company yet.
Founders appear once a person is matched to the company through its own patents, grants or filings. We never infer people from social profiles.
Checked: USPTO inventors; federal award principal investigators; SEC Form D related persons · Oct 23, 2026
Claim this profile to add your teamWhat it has protected
USPTO · 3 granted of 14- GrantedMETHODS OF TREATING COMPLEMENT MEDIATED DISEASES WITH FUSION PROTEIN CONSTRUCTS COMPRISING ANTI-C3d ANTIBODY AND A COMPLEMENT MODULATORUSPTOUS 11,879,008
- GrantedFUSION PROTEIN CONSTRUCTS COMPRISING ANTI-C3d ANTIBODY AND CR1 POLYPEPTIDEUSPTOUS 11,053,305
- GrantedFUSION PROTEIN CONSTRUCTS COMPRISING ANTI-C3d ANTIBODY AND FACTOR HUSPTOUS 11,053,306
Show all 14 patent records
- METHODS OF TREATING COMPLEMENT MEDIATED DISEASES WITH FUSION PROTEIN CONSTRUCTS COMPRISING ANTI-C3d ANTIBODY AND A COMPLEMENT MODULATORJan 23, 2024 · US 11,879,008Granted
- FUSION PROTEIN CONSTRUCTS COMPRISING ANTI-C3d ANTIBODY AND CR1 POLYPEPTIDEJul 6, 2021 · US 11,053,305Granted
- FUSION PROTEIN CONSTRUCTS COMPRISING ANTI-C3d ANTIBODY AND FACTOR HJul 6, 2021 · US 11,053,306Granted
- Treatment Of Complement-associated Renal DiseasesApplication 63700980Pending
- Treatment Of Atopic DermatitisApplication PCTUS2024040285Pending
- Treatment Of Hair-loss DisorderApplication PCTUS2024040311Pending
- Treatment Of Anca-associated VasculitisApplication 63546329Pending
- Treatment Of Complement-associated Renal DiseasesApplication 63546330Pending
- Targeted Treatment of Complement-Mediated Disease Through Local Complement Inhibition Based on Urinary uC5b-9 DetectionApplication 63527123Pending
- Fusion Protein Constructs For Complement Associated DiseaseApplication PCTUS2019065741Pending
- Treatment Of Hair-loss DisorderApplication 63516534Pending
- Fusion Protein Constructs For Complement Associated DiseaseApplication 62778014Pending
- Treatment Of Atopic DermatitisApplication 63516535Pending
- Treatment Of Anca-associated VasculitisApplication 63700966Pending
Related companies, and why
- ENTRINSIC HEALTH SOLUTIONS, INC.Similar federal contract value in Biotech · null in contracts
- Vivaldi Biosciences IncSimilar federal contract value in Biotech · null in contracts
- PAION AGSimilar federal contract value in Biotech · null in contracts
- Mytos, Inc.Similar federal contract value in Biotech · null in contracts
- CollPlant Biotechnologies LtdSimilar federal contract value in Biotech · null in contracts
- Xenetic Biosciences, Inc.Similar federal contract value in Biotech · null in contracts
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.
Sources
Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.
How to read this page
Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.
Data freshness
SEC Form D filings through . SBIR and STTR awards through .